Abstract
The last two years have seen a renaissance of monoclonal antibodies for the treatment of disease. Of the eight antibodies currently approved for human therapy, two are for the treatment of cancer. In large part, the revival of antibodies has been driven by technology developments geared toward making antibodies less likely to elicit an anti-antibody response in humans. The development of transgenic mice, XenoMouse™ animals, capable of making fully human antibodies offers new opportunities for generating antibodies of therapeutic quality. Recently, this technology has been applied to the generation of a fully human antibody to the epidermal growth factor receptor. A description of the development of this antibody serves to illustrate the power and ease of use of XenoMouse technology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leget GA, Czuczman MS: Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10: 548–551, 1998
Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21: 309–318, 1999
Abramowicz D, Crusiaux A, Goldman M: Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 327: 736, 1992
Morrison SL, Oi VT: Chimeric Immunoglobulin Genes, Immunoglobulin Genes. Academic Press, London, l989, p. 260
Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332: 323–327, 1988
Green LL, Jakobovits A: Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J Exp Med 188: 483–495, 1998
Yang X-D, Corvalan JRF, Wang P, Roy CM-N, Davis CG: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 66: 401–410, 1999
Mendez MJ, Green LL, Corvalan JRF, Jia X-C, Maynard-Currie CE, Yang X-D, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM-N, Abderrahim H, Kirsehenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Finer MH, Davis CG, Zsebo KM, Jakobovits A: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genetics 15: 146–156, 1997
Brezinschek HP, Brezinschek RI, Lipsky PE: Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 155: 190–202, 1995
Yang X-Y, Jia X-C, Corvalan JRF, Wang P, Davis CG, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236–1243, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, C.G., Gallo, M.L. & Corvalan, J.R. Transgenic Mice as a Source of Fully Human Antibodies for the Treatment of Cancer. Cancer Metastasis Rev 18, 421–425 (1999). https://doi.org/10.1023/A:1006321231510
Issue Date:
DOI: https://doi.org/10.1023/A:1006321231510